Verus Financial Partners Inc. Sells 108 Shares of Johnson & Johnson $JNJ

Verus Financial Partners Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 2.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,168 shares of the company’s stock after selling 108 shares during the period. Verus Financial Partners Inc.’s holdings in Johnson & Johnson were worth $651,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on JNJ shares. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. HSBC boosted their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $188.88.

Johnson & Johnson Price Performance

JNJ stock opened at $188.51 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $189.78. The stock has a market cap of $453.98 billion, a PE ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. The firm has a 50 day simple moving average of $176.18 and a two-hundred day simple moving average of $162.83.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.